Airsupra is a pressurized metered dose inhaler containing a combination of albuterol, a SABA, and budesonide, an ICS.

Modeling study shows decrease in prevalence of both obesity and stroke under Standard Time, Daylight Saving Time versus current polic.y ...

The REACH study included data from 58,336 Medicare patients aged 66 years and older with T2D and ASCVD who had initiated either semaglutide or dulaglutide.

The SURPASS-PEDS trial was a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of tirzepatide in children and adolescents aged 10 to less than 18 years old with T2D ...

Cumulative influenza-associated hospitalization rate surpassed end-of-season rates during period starting with 2010 to 2011 season.

On Tuesday, the US Food and Drug Administration (FDA) released more than 100 warning letters aimed at both drugmakers and online health companies. Among them: Hims & Hers, a telehealth platform that ...

Tirzepatide offers more favorable return on investment, but greater benefits seen at lower costs for Roux-en-Y gastric bypass ...

So far, large federal studies have shown no higher risk for major birth defects, miscarriage or other complications.

The Food and Drug Administration (FDA) has approved Bosaya ™ (denosumab-kyqq) and Aukelso ™ (denosumab-kyqq), biosimilars to Prolia ® (denosumab) and Xgeva ® (denosumab), respectively.

Garetosmab is a fully-human monoclonal antibody designed to bind and neutralize Activin A, a major promoter of HO in patients with FOP.

The ACHIEVE-3 trial was a 52-week, randomized, open-label study that included 1698 T2D patients inadequately controlled on metformin.

Findings show discomfort primarily exists among gynecologists seeing patients with a history of endometrial or epithelial ovarian cancer ...